The role of nuclear factor-κB in the biology and treatment of multiple myeloma

Seminars in Oncology

Volumn 28, Issue 6, 2001, Pages 626-633

  Berenson, J R ^a   Ma, H M ^a   Vescio, R ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN KAPPA CHAIN; INHIBITOR PROTEIN; MELPHALAN; MITOXANTRONE; UBIQUITIN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CONJUGATION; CONTROLLED STUDY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN POLYMORPHISM; REVIEW;

EID: 0035207110     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.29542     Document Type: Review

References (44)

1. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
2. Management of multiple myeloma today
3. Update on the treatment of multiple myeloma
4. Heterogeneous chromosomal aberrations generate 3′ truncations of the NFKB2/lyt-10 gene in lymphoid malignancies
5. Rel/NF-κB/IκB proteins and cancer
6. Mutations in the IκBα gene in Hodgkin's disease suggest a turnout suppressor role for IκBα
7. Aberrant rel/nfkb genes and activity in human cancer
8. Constitutive expression of NF-κB is a characteristic feature of mycosis fungoides: Implications for apoptosis resistance and pathogenesis
9. Signal transduction through NF-κB
10. Control of apoptosis by Rel/NF-κB transcription factors
11. IκB proteins: Structure, function and regulation
12. NF-κB: Ten years after
13. Regulation of the DNA binding activity of NF-κB
14. Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-κB/Rel transcription factors
15. The IκB proteins: Multifunctional regulators of Rel/NF-κB transcription factors
16. Mutual regulation of the transcriptional activator NF-κB and its inhibitor, IκB-α
17. Rapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB
18. Proteolytic degradation of MAD3 (IκBα) and enhanced processing of the NF-κB precursor p105 are obligatory steps in the activation of NF-κB
19. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB
20. NF-κB activation is related to the resistance of lung cancer cells to TNF-α-induced apoptosis
21. Nuclear factorκB/IκB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells
22. Tumor metastasis and the reciprocal regulation of prometastatic and anti-metastatic factors by nuclear factor KB
23. Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2
24. Protease inhibitor-induced apoptosis: Accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition
25. Proteasome inhibition measurements: Clinical application
26. Proteasome inhibition: A new strategy in cancer treatment
27. c-Myc proteolysis by the ubiquitin-proteasome pathway: Stabilization of c-Myc in Burkitt's lymphoma cells
28. The proteasome inhibitor PS-341 in cancer therapy
29. Ubiquitin-proteasome inhibition enhances apoptosis of human pancreatic cancer cells
30. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
31. A randomized trial of chemotherapy with or without estrogenic recruitment in locally advanced breast cancer
32. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
33. Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor-κB-dependent mechanism
34. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-κB inhibition
35. Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation
36. Combined effects of angiostatin and ionizing radiation in antitumour therapy
37. Malignant gastrointestinal lymphomas in patients with AIDS
38. Multiple myeloma and chronic lymphocytic leukemia
39. Steroid treatment of shock lung-Time for re-evaluation?
40. An IκBα inhibitor causes leukemia cell death through a p38 MAP kinase-dependent, NF-κB-independent mechanism
41. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells
42. Rapid detection of octamer binding proteins with 'mini-extracts,' prepared from a small number of cells
43. Identify specific polymorphisms of IκBα in tumor cell from multiple myeloma patients
44. PS-341 is active in multiple myeloma: Preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with multiple myeloma